Stockscreener 앱 받기
11.41
0.74%
-0.085
전일 마감가:
$11.50
열려 있는:
$11.5
하루 거래량:
197.45K
Relative Volume:
0.92
시가총액:
$913.07M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-13.46%
1개월 성능:
-3.67%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.05
$11.53
1주일 범위
$11.05
$13.44
52주 변동 폭
$8.70
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
명칭
Bridgebio Oncology Therapeutics Inc
전화
857 702 0377
주소
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
BBOT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
11.41 | 919.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Raymond James | Outperform |
| 2025-12-05 | 개시 | Morgan Stanley | Overweight |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc 주식(BBOT)의 최신 뉴스
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
BBOT: Robust efficacy and safety data position these assets as leaders in KRAS-targeted cancer therapy - TradingView — Track All Markets
Raymond James Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Outperform Recommendation - Nasdaq
BridgeBio Oncology stock initiated with Outperform rating at Raymond James By Investing.com - Investing.com Nigeria
Raymond James Initiates BridgeBio Oncology Therapeutics at Outperform With $24 Price Target - marketscreener.com
BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com
BridgeBio Oncology stock price target raised to $32 from $25 at Leerink - Investing.com Canada
Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock By Investing.com - Investing.com Canada
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley - Investing.com
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley By Investing.com - Investing.com India
BBOT: Promising efficacy and safety for three RAS-pathway inhibitors, with key data expected in 2026 - TradingView — Track All Markets
BridgeBio Oncology reports positive data from RAS-pathway cancer trials - Investing.com
BridgeBio Oncology reports positive data from RAS-pathway cancer trials By Investing.com - Investing.com Nigeria
BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs - TradingView — Track All Markets
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs - The Manila Times
BridgeBio Oncology Therapeutics, Inc.Common Stock (NQ: BBOT - FinancialContent
BridgeBio Oncology Therapeutics, Inc.(NasdaqGM: BBOT) added to S&P Global BMI Index - marketscreener.com
BridgeBio Oncology Therapeutics Earnings Notes - Trefis
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance
Wedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - MSN
BridgeBio Oncology Therapeutics (BBOT) updates CEO option grant terms - Stock Titan
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wedbush Reiterates Outperform Rating for BBOT; Price Target Unch - GuruFocus
BridgeBio Oncology initiated with an overweight at Morgan Stanley - MSN
Contact | Statesman-ExaminerBBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga
BridgeBio Oncology Therapeutics, Inc. Announces Late-Breaking Preclinical Data on BBO-10203, a First-In-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium - marketscreener.com
BridgeBio Oncology stock reaches all-time high at 14.87 USD By Investing.com - Investing.com Canada
BridgeBio Oncology stock reaches all-time high at 14.87 USD - Investing.com India
Morgan Stanley Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Overweight Recommendation - Nasdaq
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
BridgeBio Oncology: Positioned for Growth with Innovative RAS-Targeted Therapies - TipRanks
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
BridgeBio Oncology initiated with an Overweight at Morgan Stanley - TipRanks
Morgan Stanley initiates coverage on BridgeBio Oncology stock with Overweight rating - Investing.com India
BBOT: All three oncology programs progressed in 2025, with major data readouts and strategic decisions set for 2026 - TradingView — Track All Markets
BBOT: Wedbush Reiterates Outperform Rating with $25 Target | BBO - GuruFocus
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
BBOT to Participate in Upcoming December Investor Healthcare Conferences - The Manila Times
BridgeBio Oncology Therapeutics Reports Q3 2025 Progress - TipRanks
Oppenheimer Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
BridgeBio Oncology Therapeutics, Inc. (BBOT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Decoding BridgeBio Oncology Therapeutics Inc (BBOT): A Strategic SWOT Insight - GuruFocus
Oppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq
BBOT Analyst Rating Update: Oppenheimer Lowers Price Target | BB - GuruFocus
Bridgebio Oncology Therapeutics Inc (BBOT) 재무 분석
Bridgebio Oncology Therapeutics Inc (BBOT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):